Please assess the completion status of the following clinical trial:

Trial Title: Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of Waldenstrom's macroglobulinemia~* CD20 positive by bone marrow immunohistochemistry or flow cytometry~* Presence of monoclonal paraprotein~* IgM level at least 2 times upper limit of normal (ULN)~PATIENT CHARACTERISTICS:~Age:~* Over 18~Performance status:~* ECOG 0-2~Life expectancy:~* At least 6 months~Hematopoietic:~* Absolute neutrophil count greater than 1,000/mm\^3~* Platelet count greater than 25,000/mm\^3~Hepatic:~* Bilirubin less than 2.5 times ULN~* SGOT less than 2.5 times ULN~Renal:~* Creatinine less than 2.5 mg/dL~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 6 months after study~* No serious comorbid disease~* No uncontrolled bacterial, fungal, or viral infection~* No other active malignancy~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior rituximab~* No prior nucleoside analogue therapy~Chemotherapy:~* At least 30 days since prior chemotherapy~Endocrine therapy:~* At least 30 days since prior steroid therapy~* No concurrent corticosteroids~Radiotherapy:~* At least 30 days since prior radiotherapy~Surgery:~* Not specified~Other:~* No more than 2 prior courses of therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).